Seven-compound research blend formulated for parallel pathway studies.
Next-generation GLP receptor research compound. Multi-variant dosing.
Eight-compound proprietary research blend. Single reconstitution protocol.
Co-formulated BPC-157 and TB-500 for combined research protocols.